Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome

Wanek Program Regenerative Medicine Pipeline, Muhammad Y Qureshi, Allison K Cabalka, Shakila P Khan, Donald J Hagler, Dawit T Haile, Bryan C Cannon, Timothy M Olson, Susana Cantero-Peral, Allan B Dietz, Darcie J Radel, Nathan W Taggart, Angela M Kelle, Vilmarie Rodriguez, Joseph A Dearani, Patrick W O'Leary

Research output: Contribution to journalArticlepeer-review


Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow-derived mononuclear cell administration for ventricular dysfunction, 23 years after Fontan operation in a patient with hypoplastic left heart syndrome. The cells were delivered into the coronary circulation by cardiac catheterization. Ventricular size decreased and several parameters reflecting ventricular function improved, with maximum change noted 3 months after cell delivery. Such regenerative therapeutic options may help in delaying and preventing cardiac transplant.

Original languageEnglish (US)
Pages (from-to)185-191
Number of pages7
JournalMayo Clinic proceedings. Innovations, quality & outcomes
Issue number2
StatePublished - Sep 2017
Externally publishedYes


Dive into the research topics of 'Cell-Based Therapy for Myocardial Dysfunction After Fontan Operation in Hypoplastic Left Heart Syndrome'. Together they form a unique fingerprint.

Cite this